Halozyme Therapeutics (HALO) Short Interest Ratio & Short Volume → It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad) Free HALO Stock Alerts $50.85 -0.59 (-1.15%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Halozyme Therapeutics Short Interest DataCurrent Short Interest8,560,000 sharesPrevious Short Interest8,410,000 sharesChange Vs. Previous Month+1.78%Dollar Volume Sold Short$392.22 millionShort Interest Ratio8.7 Days to CoverLast Record DateMay 15, 2024Outstanding Shares127,270,000 sharesFloat Size125,850,000 sharesShort Percent of Float6.80%Today's Trading Volume1,849,600 sharesAverage Trading Volume1,219,075 sharesToday's Volume Vs. Average152% Short Selling Halozyme Therapeutics ? Sign up to receive the latest short interest report for Halozyme Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartHALO Short Interest Over TimeHALO Days to Cover Over TimeHALO Percentage of Float Shorted Over Time Ad StocksToTradeWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution Halozyme Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/20248,560,000 shares $392.22 million +1.8%6.8%8.7 $45.82 4/30/20248,410,000 shares $320.42 million +2.1%6.7%8.2 $38.10 4/15/20248,240,000 shares $319.05 million +4.4%6.6%7.8 $38.72 3/31/20247,890,000 shares $320.97 million -3.8%6.3%6.1 $40.68 3/15/20248,200,000 shares $335.05 million +1.5%6.5%6.1 $40.86 2/29/20248,080,000 shares $321.66 million +5.6%6.4%5.9 $39.81 Get the Latest News and Ratings for HALO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/20247,650,000 shares $274.71 million +0.1%6.1%5.7 $35.91 1/31/20247,640,000 shares $258.61 million +6.6%5.8%5.7 $33.85 1/15/20247,170,000 shares $246.86 million -2.5%5.5%5.7 $34.43 12/31/20237,350,000 shares $271.66 million -2.0%5.6%7 $36.96 12/15/20237,500,000 shares $292.65 million +5.2%5.7%8 $39.02 11/30/20237,130,000 shares $275.29 million +2.3%5.5%7.9 $38.61 11/15/20236,970,000 shares $274.20 million +5.9%5.3%8 $39.34 10/31/20236,580,000 shares $222.86 million -0.5%5.0%7.8 $33.87 10/15/20236,610,000 shares $241.60 million +2.3%5.1%7.8 $36.55 9/30/20236,460,000 shares $246.77 million -5.6%5.0%6.9 $38.20 9/15/20236,840,000 shares $268.26 million No Change5.2%6.9 $39.22 8/31/20236,840,000 shares $291.11 million -6.3%5.2%6.6 $42.56 8/15/20237,300,000 shares $321.35 million -3.2%5.6%7 $44.02 7/31/20237,540,000 shares $323.92 million +7.7%5.8%6.6 $42.96 7/15/20237,000,000 shares $267.54 million +5.4%5.4%5.8 $38.22 6/30/20236,640,000 shares $239.50 million -1.5%5.1%5.7 $36.07 6/15/20236,740,000 shares $230.24 million -3.2%5.2%5.1 $34.16 5/31/20236,960,000 shares $225.71 million +5.6%5.3%4.5 $32.43 5/15/20236,590,000 shares $223.40 million +2.3%5.1%4 $33.90 4/30/20236,440,000 shares $206.92 million -2.0%4.8%4.1 $32.13 4/15/20236,570,000 shares $234.22 million +0.5%4.9%4.3 $35.65 3/31/20236,540,000 shares $249.76 million -0.9%4.9%4.1 $38.19 3/15/20236,600,000 shares $264.33 million -4.2%4.9%4.5 $40.05 2/28/20236,890,000 shares $330.65 million +1.8%5.2%5.6 $47.99 2/15/20236,770,000 shares $333.08 million -3.4%5.1%5.6 $49.20 1/31/20237,010,000 shares $362.91 million -19.2%5.2%5.5 $51.77 1/15/20238,670,000 shares $436.45 million -4.8%6.5%6.8 $50.34 12/30/20229,110,000 shares $518.36 million -3.9%6.8%7.9 $56.90 12/15/20229,480,000 shares $540.64 million -2.0%7.1%8 $57.03 11/30/20229,670,000 shares $553.70 million -4.6%7.2%7.9 $57.26 11/15/202210,140,000 shares $547.76 million -6.3%7.6%8.7 $54.02 10/31/202210,820,000 shares $517.30 million -5.6%7.9%8.3 $47.81 10/15/202211,460,000 shares $506.19 million -5.4%8.4%8.7 $44.17 9/30/202212,110,000 shares $478.83 million +11.6%8.9%9.1 $39.54Write this ticker symbol down… (Ad)A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution 9/15/202210,850,000 shares $459.28 million +1.6%8.0%7.6 $42.33 8/31/202210,680,000 shares $435.00 million +18.9%7.8%7.9 $40.73 8/15/20228,980,000 shares $386.95 million -1.4%6.6%6.7 $43.09 7/31/20229,110,000 shares $445.48 million +2.4%6.7%7.7 $48.90 7/15/20228,900,000 shares $437.52 million +9.1%6.9%7.6 $49.16 6/30/20228,160,000 shares $359.04 million -3.8%6.3%7.1 $44.00 6/15/20228,480,000 shares $378.46 million +1.3%6.5%8 $44.63 5/31/20228,370,000 shares $384.85 million +5.4%6.1%8.5 $45.98 5/15/20227,940,000 shares $320.93 million -1.2%5.8%8.3 $40.42 4/30/20228,040,000 shares $320.80 million +8.8%5.9%9.1 $39.90 4/15/20227,390,000 shares $312.38 million +3.5%5.4%8.3 $42.27 3/31/20227,140,000 shares $284.74 million +3.9%5.2%7.8 $39.88 3/15/20226,870,000 shares $242.92 million +5.5%5.1%7.8 $35.36 2/28/20226,510,000 shares $230.91 million +3.5%4.8%6.7 $35.47 2/15/20226,290,000 shares $216.56 million -0.6%4.6%6.3 $34.43 1/31/20226,330,000 shares $219.08 million +1.8%4.6%6.5 $34.61 1/15/20226,220,000 shares $221.18 million -4.6%N/A6.6 $35.56 12/31/20216,520,000 shares $262.17 million +0.2%4.7%7.4 $40.21 12/15/20216,510,000 shares $240.41 million +2.5%4.7%7.3 $36.93 11/30/20216,350,000 shares $208.79 million +6.0%4.6%8 $32.88 11/15/20215,990,000 shares $228.76 million -6.3%4.3%7.9 $38.19 10/29/20216,390,000 shares $243.27 million +6.2%4.6%8.3 $38.07 10/15/20216,020,000 shares $227.32 million -2.1%4.3%7.9 $37.76 9/30/20216,150,000 shares $250.18 million +7.3%4.4%8 $40.68 9/15/20215,730,000 shares $236.36 million -3.9%4.1%7.8 $41.25 8/31/20215,960,000 shares $250.26 million +5.1%4.3%7.7 $41.99 8/13/20215,670,000 shares $235.13 million -0.9%4.1%7 $41.47 7/30/20215,720,000 shares $236.41 million -10.5%4.1%6.4 $41.33 7/15/20216,390,000 shares $274.13 million -1.2%4.6%7.2 $42.90 6/30/20216,470,000 shares $293.80 million No Change4.6%7 $45.41 6/15/20216,470,000 shares $277.89 million -5.6%4.6%6.3 $42.95 5/28/20216,850,000 shares $283.66 million -4.5%4.9%6.7 $41.41 5/14/20217,170,000 shares $299.49 million -3.5%5.1%5.3 $41.77 4/30/20217,430,000 shares $381.23 million +5.5%5.3%5.5 $51.31 4/15/20217,040,000 shares $323.49 million -9.4%5.0%5.1 $45.95 3/31/20217,770,000 shares $319.27 million -6.2%5.6%5.4 $41.09 3/15/20218,280,000 shares $367.38 million -33.3%6.3%5.9 $44.37 2/26/202112,420,000 shares $587.59 million -13.9%9.4%8.7 $47.31 2/12/202114,430,000 shares $717.75 million -5.1%10.9%10.9 $49.74 1/29/202115,200,000 shares $728.23 million -0.3%11.6%8.8 $47.91 1/15/202115,250,000 shares $717.51 million +2.7%11.7%8.1 $47.05 12/31/202014,850,000 shares $632.46 million -4.0%11.4%7.7 $42.59 12/15/202015,460,000 shares $647.00 million -7.0%11.8%8.1 $41.85 11/30/202016,630,000 shares $669.02 million +13.9%12.7%8.7 $40.23 11/15/202014,600,000 shares $567.21 million +8.6%11.2%8 $38.85 10/30/202013,450,000 shares $388.57 million -10.2%10.3%9.6 $28.89 10/15/202014,980,000 shares $428.28 million +2.4%11.4%13.9 $28.59 9/30/202014,630,000 shares $384.48 million -4.2%N/A15 $26.28 9/15/202015,270,000 shares $420.38 million -1.0%11.6%13.9 $27.53 8/31/202015,430,000 shares $447.47 million -3.9%11.7%13.9 $29.00Write this ticker symbol down… (Ad)A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution 8/14/202016,050,000 shares $447.63 million -0.7%12.2%13.5 $27.89 7/31/202016,170,000 shares $439.66 million -3.4%12.7%12.3 $27.19 7/15/202016,730,000 shares $454.89 million +2.3%13.2%11.6 $27.19 6/30/202016,350,000 shares $422.16 million +0.8%12.9%11.2 $25.82 6/15/202016,220,000 shares $375.49 million +0.7%12.8%11.5 $23.15 5/29/202016,110,000 shares $390.99 million +2.5%12.7%9.8 $24.27 5/15/202015,720,000 shares $373.82 million +1.6%12.4%8.7 $23.78 4/30/202015,480,000 shares $350.70 million +9.4%12.0%8.7 $22.66 4/15/202014,150,000 shares $251.30 million +1.1%11.0%8 $17.76 3/31/202013,990,000 shares $327.65 million -0.8%10.8%7.5 $23.42 3/13/202014,109,100 shares $253.68 million +1.7%10.9%7.5 $17.98 2/28/202013,870,000 shares $233.29 million +7.9%10.7%8.8 $16.82 2/14/202012,850,000 shares $249.68 million -1.0%9.9%8.3 $19.43 1/31/202012,980,000 shares $274.79 million +4.7%10.2%7.2 $21.17 1/15/202012,400,000 shares $245.89 million -0.2%9.7%6.6 $19.83 12/31/201912,430,000 shares $237.04 million -0.9%9.1%7.2 $19.07 8/15/20197,517,400 shares $119.68 million -5.5%5.8%8.5 $15.92 HALO Short Interest - Frequently Asked Questions What is Halozyme Therapeutics' current short interest? Short interest is the volume of Halozyme Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 8,560,000 shares of HALO short. 6.80% of Halozyme Therapeutics' shares are currently sold short. Learn More on Halozyme Therapeutics' current short interest. What is a good short interest ratio for Halozyme Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. HALO shares currently have a short interest ratio of 9.0. Learn More on Halozyme Therapeutics's short interest ratio. Which institutional investors are shorting Halozyme Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Halozyme Therapeutics: Walleye Trading LLC, Torno Capital LLC, Concourse Financial Group Securities Inc., Oak Hill Wealth Advisors LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Halozyme Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.80% of Halozyme Therapeutics' floating shares are currently sold short. Is Halozyme Therapeutics' short interest increasing or decreasing? Halozyme Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 8,560,000 shares, an increase of 1.8% from the previous total of 8,410,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Halozyme Therapeutics' float size? Halozyme Therapeutics currently has issued a total of 127,270,000 shares. Some of Halozyme Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Halozyme Therapeutics currently has a public float of 125,850,000 shares. How does Halozyme Therapeutics' short interest compare to its competitors? 6.80% of Halozyme Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Halozyme Therapeutics: Twist Bioscience Co. (18.38%), Iovance Biotherapeutics, Inc. (22.90%), Relay Therapeutics, Inc. (8.96%), Adaptive Biotechnologies Co. (8.92%), Fate Therapeutics, Inc. (18.28%), Allogene Therapeutics, Inc. (30.07%), Kodiak Sciences Inc. (3.76%), Alnylam Pharmaceuticals, Inc. (2.01%), BioMarin Pharmaceutical Inc. (1.97%), Neurocrine Biosciences, Inc. (1.85%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Halozyme Therapeutics stock? Short selling HALO is an investing strategy that aims to generate trading profit from Halozyme Therapeutics as its price is falling. HALO shares are trading down $0.59 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Halozyme Therapeutics? A short squeeze for Halozyme Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of HALO, which in turn drives the price of the stock up even further. How often is Halozyme Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HALO, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: TWST Short Interest IOVA Short Interest RLAY Short Interest ADPT Short Interest FATE Short Interest ALLO Short Interest KOD Short Interest ALNY Short Interest BMRN Short Interest NBIX Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:HALO) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.